SCHEMBL12896193

SCHEMBL12896193

CC(C)Oc1ccc(F)c(-c2nnco2)c1

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 5/20 0.50
▸ PIM1 P11309 2/20 0.43
▸ PIM3 Q86V86 2/20 0.43
▸ PIM2 Q9P1W9 2/20 0.43
▸ PTGDR Q13258 1/20 0.41
▸ TRPV3 Q8NET8 1/20 0.40
▸ DHODH Q02127 1/20 0.40
▸ PDE2A O00408 1/20 0.40
▸ PDE10A Q9Y233 1/20 0.40
▸ FFAR4 Q5NUL3 5/20 0.40
▸ TSHR P16473 2/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12925143 0.84 NOTUM (0.55) NOTUMPDE2APDE10ATSHRMAPK1
SCHEMBL12896182 0.75 NOTUM (0.62) NOTUMTSHRMAPK1NPC1RAB9A
SCHEMBL3173819 0.75 NOTUM (0.62) NOTUMTSHRMAPK1NPC1RAB9A
SCHEMBL12896204 0.74 NOTUM (0.70) NOTUMPIM1PIM3PIM2TSHR
SCHEMBL12896192 0.72 NOTUM (0.49) NOTUMPIM1PIM3PIM2TSHR
SCHEMBL17148984 0.72 NOTUM (0.59) NOTUMTSHRMAPK1NPC1RAB9A
SCHEMBL13019358 0.70 KMT2A (0.54) NOTUMPIM1PIM3PIM2TSHR
SCHEMBL24215370 0.69 NOTUM (0.58) NOTUMTSHRMAPK1
SCHEMBL1020456 0.69 ALDH1A1 (0.47) TRPV3FFAR4
SCHEMBL30829775 0.69 ALDH1A1 (0.47) TRPV3FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9149465-B2 Isoxazolines as inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-10-06 — — US disclosed
US-8927551-B2 Isoxazolines as inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-01-06 — — US disclosed
US-20110034437-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2011-02-10 — — US disclosed
US-20110028482-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2011-02-03 — — US disclosed
US-20110028478-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2011-02-03 — — US disclosed
US-20110028478-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2011-02-03 — — US disclosed
US-20110028482-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2011-02-03 — — US disclosed
WO-2010135360-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2010-11-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034437-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, HRH2 NOTUM 390/4885PIM1 4739/4885PIM3 4734/4885
US-20110028478-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, HRH2 NOTUM 390/4885PIM1 4739/4885PIM3 4734/4885
US-20110028482-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, HRH2 NOTUM 390/4885PIM1 4739/4885PIM3 4734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback